

# Global Tretten Or Novothirteen Market Forecast: Key Growth Drivers, Trends, and Opportunities from 2025 to 2034

*Updated 2025 Market Reports Released:  
Trends, Forecasts to 2034 – Early  
Purchase Your Competitive Edge Today!*

LONDON, GREATER LONDON, UNITED KINGDOM, February 10, 2025

/EINPresswire.com/ -- The [tretten or novothirteen market size](#) has seen

significant growth in recent years. It is

projected to grow from \$XX million in 2024 to \$XX million in 2025, evident of a compound annual growth rate CAGR of XX%. What is driving this growth? The surge can be attributed to several key factors, including improved insurance coverage and reimbursement policies, increasing prevalence of genetic disorders, escalating demand for effective clotting factor replacement, and rising awareness and investment in rare disease research.

How will the tretten or novothirteen market fare in the forecast period?

The market size is expected to see an increasing trend in the next few years, propelling it to reach \$XX million in 2029 at a compound annual growth rate CAGR of XX%. This forecasted growth can be attributed to a shift towards prophylactic treatment regimens, development of extended half-life therapies, transition from plasma-derived therapies to recombinant therapies, and an increased focus on personalized medicine and healthcare access.

Also shaping the market landscape are major anticipated trends, including advancements in recombinant technology, drug development, biotechnology, and clotting factor replacement, as well as progress in clinical research.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20344&type=smp>

What Drives The [Tretten or Novothirteen Market Growth](#)?

A key growth driver for the market is the increasing awareness of rare bleeding disorders,



including hemophilia, von Willebrand disease, and Factor XIII deficiency. They are uncommon conditions that can impair the blood's ability to clot, posing health risks to individuals. Boosted by improved diagnostic capabilities, patient advocacy efforts, and educational campaigns, this rise in awareness is driving earlier detection, better treatment access, and improved patient outcomes. For instance, in 2022-2023, 2,069 individuals in the UK including 374 with severe disease and 351 with moderate disease were diagnosed with hemophilia B, according to the UK-based National Institute for Health and Care Excellence as of March 2024.

Crucial in treating these disorders is Tretten, also known as NovoThirteen, which provides a recombinant form of activated Factor XIII for blood clot stabilization, thus reducing the risk of bleeding in patients with Factor XIII deficiency. Given these insights, it can be seen how increased awareness of rare bleeding disorders can drive growth in the tretten or novothirteen market.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/tretten-or-novothirteen-global-market-report>

Who Are The Key Players In The Tretten or Novothirteen Market?

Major companies operating in the tretten or novothirteen market include Novo Nordisk A/S, contributing significantly to advancements in the field.

How Is The Tretten or Novothirteen Market Segmented?

The tretten or novothirteen market report includes a comprehensive segmentation analysis, with the market divided as follows:

- 1 By Clinical Indication: Hemophilia B; Surgical Prophylaxis
- 2 By Formulation: Lyophilized Powder; Intravenous Solution
- 3 By Distribution Channel: Hospital And Clinics; Retail And Specialty Pharmacies
- 4 By End User: Adult Patient; Pediatric Patients

The report's regional insights reveal that North America was the largest market for tretten or novothirteen in 2024. Additionally, the report covers a wide geographical scope, including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse for more similar reports-

Intravenous Infusion Pumps Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/intravenous-infusion-pumps-global-market-report>

Ambulatory IV infusion Pumps Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/ambulatory-iv-infusion-pumps-global-market-report>

## [market-report](#)

Implantable Infusion Pumps Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/implantable-infusion-pumps-global-market-report>

The "Tretten Or Novothirteen Global Market Report 2025" by The Business Research Company delivers comprehensive, data-rich research and insights across 27 industries in 60+ geographies, driven by a database of 1.5 million datasets. These invaluable assets are complemented by in-depth secondary research and unique insights from industry leaders to ensure the relevancy and accuracy of information.

For more insights, visit The Business Research Company's official website:

<https://www.thebusinessresearchcompany.com/>

or reach out at the following contacts: Americas +1 3156230293, Asia +44 2071930708, Europe +44 2071930708, or email us at [info@tbrc.info](mailto:info@tbrc.info).

Stay connected for latest updates via

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>,

YouTube: [https://www.youtube.com/channel/UC24\\_fI0rV8cR5DxlCpgmyFQ](https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ), or the

Global Market Model site: <https://www.thebusinessresearchcompany.com/global-market-model>.

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/783894610>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.